OVID THERAPEUTICS INC.

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

18 Oct 2023 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

10 Oct 2023 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

26 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

20 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

04 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

01 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

28 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Added to Russell 3000® Index

26 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

05 May 2023 06:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

01 May 2023 05:00:00 By Nasdaq GlobeNewswire

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

27 Apr 2023 13:30:14 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

10 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

13 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

09 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

08 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

28 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

08 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

05 Jan 2023 07:00:45 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

02 Dec 2022 09:00:00 By Nasdaq GlobeNewswire